Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier
|
|
- Colin Newman
- 5 years ago
- Views:
Transcription
1 Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) (A)-Testing Criteria Noonan syndrome NS1, NS3, NS4, NS5 OMIM number for disease NS1 # NS3 # NS4 # NS5 # LEOPARD syndrome LENTIGINOSIS,CARDIOMYOPATHIC MULTIPLE LENTIGINES SYNDROME LS1, LS2 Gene name and description (please provide any alternative names you wish listed) LS1 #15110 LS2 # PTPN11 - Protein Tyrosine Phosphatase, Non-receptor type 11 SOS1 Son Of Sevenless, Drosophila, homolog 1 KRAS Kirsten Rat Sarcoma Viral Oncogene Homolog 1 RAF1 Murine Leukaemia Viral Oncogene Homolog 1 OMIM number for Gene PTPN11 - * SOS1 - * KRAS - * Mutational spectrum for which you test Technical Method (s) RAF1 - * Missense mutations Stage 1 dhplc of exons 2,3,4,7,8,12 and 13 of PTPN11 Stage 2 dhplc of exons 6,13 and 16 of RAF1 and exons 3, 6 and 10 of SOS1 Stage 3 dhplc of exons 7,8,11,13,14 and 16 of SOS1 and exons 1,2,3,4, and 4 isoform b KRAS Validation Process Note please explain how this test has been validated for use in your laboratory Variants will be confirmed by bi-directional sequencing on reamplified fragments Analysis of known mutation positive control samples. These covered a range of mutations in various exons for each gene. All mutations were identified by our testing strategy. We have extensive experience with dhplc and sequencing and can be confident in the sensitivity of our approach. This strategy also provides an efficient and cost effective service. 1
2 Are you providing this test already? If yes, how many reports have you produced? Please give the number of mutation positive/negative samples you have reported For how long have you been providing this service? Yes, PTPN11 (as of Summer 2007) Noonan syndrome 836 reports issued (226 positive) LEOPARD syndrome - 31 reports issued (23 positive) SOS1, RAF1, KRAS 15 positive reports PTPN11 - Exons 3 and 8 since 2002, exons 2, 3, 4, 7, 8, 12 and 13 since 2005 SOS1, RAF1 KRAS to be offered from April 2008 once service has been fully developed and validated Is there specialised local clinical/research expertise for this disease? Are you testing for other genes/diseases closely allied to this one? Please give details Your Activity How many tests do you (intend to) provide annually in your laboratory? Based on experience how many tests will be required nationally (UK)? Please identify the information on which this is based Yes No Please provide details The research laboratories at St. Georges have been working for over 10 years to clone the genes for Noonan syndrome. They were collaborators of the group who eventually identified PTPN11. They have also worked on the related genes, KRAS, SOS1 and RAF1. Prof. Patton, a consultant clinical geneticist at St. Georges, has been instrumental in this objective, and is a world-wide authority on Noonan/LEOPARD syndrome and related disorders. Costello Syndrome HRAS HRAS is part of the RAS-MAPK signalling pathway to which PTPN11, SOS1, KRAS and RAF1 also belong. The phenotypes caused by mutations in these genes overlap significantly and are thus can be difficult to differentiate clinically. ~ tests for Noonan syndrome and LEOPARD syndrome combined including all three screening stages Based on the referral rates over the past few years we estimate a UK requirement of tests for Noonan syndrome and LEOPARD syndrome combined. We only expect of these referrals to be for LEOPARD syndrome specifically but we would not alter our screening strategy in these cases because of the clinical overlap with Noonan syndrome. 2
3 Epidemiology Estimated prevalence of disease in the general UK population Please identify the information on which this is based Estimated gene frequency (Carrier frequency or allele frequency) Noonan syndrome 1 in 1,000 to 2,500 live births (Tartaglia 2001) LEOPARD syndrome Much lower but no figures available Noonan syndrome 1 in 1,000 to 2,500 (Tartaglia, 2001) Please identify the information on which this is based Estimated penetrance Please identify the information on which this is based LEOPARD syndrome - No figures available 100% penetrant no known asymptomatic carriers Target Population The essential clinical or family history features defining the target population must be described. (C)-Testing Criteria No ethnic clustering. Referrals will mainly be children but some adults with a possible clinical diagnosis of Noonan or LEOPARD syndrome. PTPN11 mutations are mainly sporadic (estimated at 60% in PTPN11). Clinical features include; Noonan syndrome PTPN11 features include, short stature, pulmonary valve stenosis, hypertrophic cardiomyopathy, skeletal deformations and characteristic facial features. Some additional genotype/phenotype correlations have been reported for the other genes. PTPN11 and KRAS mutations are also associated with Juvenile myelomonocytic leukaemia (JMML). SOS1 mutations are also associated with an increased occurrence of pulmonary stenosis, keratosis pilaris, ocular ptosis and curly hair but decreased occurrence of atrial septal defects and short stature. There is a higher incidence of hypertrophic cardiomyopathy caused by RAF1 mutations. Estimated prevalence of disease in the target population LEOPARD syndrome - multiple lentigines, congenital heart defects, sensorineural deafness, hypertelorism, a clinically defined facies and growth retardation. Mutations have been identified in PTPN11 and RAF1. No phenotypic differences between the two genes have been reported. No figures available 3
4 Intended Use (Please use the questions in Annex A to inform your answers) Please tick the relevant clinical purpose of testing YES NO Diagnosis X Treatment X Prognosis & Management X Presymptomatic testing N/A N/A Risk Assessment X 4
5 Test Characteristics Analytical sensitivity and specificity This should be based on your own laboratory data for the specific test being applied for or the analytical sensitivity and specificity of the method/technique to be used in the case of a test yet to be set up. Pre-screening using dhplc (WAVE) has proven to be 100% sensitive based on analysis of known controls. Sequencing analysis of any variants detected by dhplc provides a specificity of 100% If a number of genes will be tested, please include your testing strategy and data on the expected proportions of positive results for each part of the process. It may be helpful to include a diagram to illustrate the testing strategy. Clinical sensitivity and specificity of test in target population The clinical sensitivity of a test is the probability of a positive test result when disease is known to be present; the clinical specificity is the probability of a negative test result when disease is known to be absent. The denominator in this case is the number with the disease (for sensitivity) or the number without disease (for specificity) Noonan syndrome PTPN11 - mutations in ~45-50% of patients. SOS1 - mutations in ~10% patients RAF1 - mutations in ~3% (variable figures) patients KRAS mutations in <6% patients Therefore Clinical Sensitivity for Noonan syndrome = 60-70% LEOPARD syndrome PTPN11 mutations in ~90% of patients. RAF-1 little data available Therefore Clinical Sensitivity for LEOPARD syndrome = >90% Both conditions are 100% penetrant. Therefore Clinical Specificity = 100% 5
6 Clinical validity (positive and negative predictive value in the target population) The clinical validity of a genetic test is a measure of how well the test predicts the presence or absence of the phenotype, clinical disease or predisposition. It is measured by its positive predictive value (the probability of getting the disease given a positive test) and negative predictive value (the probability of not getting the disease given a negative test). The denominator in this case is the number of people with a positive or a negative test respectively - not the number with or without the disease. The clinical validity may be calculated knowing the sensitivity and the specificity and the prevalence of the disease in the population being studied. Positive and negative predictive values depend critically on the prevalence of the disease in the test population Positive Predictive value = 100% for Noonan and LEOPARD syndrome Negative Predictive value = 60-70% for Noonan syndrome and 90% for LEOPARD syndrome 6
7 Clinical utility of test in target population (Please refer to Appendix A) Please provide a full description of the clinical care pathway for those individuals undergoing testing. This should include details of which medical specialties will be able to refer for testing. (B)-Testing Criteria How will the test add to the management of the patient or alter clinical outcome? What impact will this test have on the NHS i.e. by removing the need for alternative management and/or investigations for this clinical population? Clinical diagnosis has been difficult and required specialist clotting and cardiac investigations. Molecular testing will simplify the process of making a diagnosis. Referrals will be accepted for suspected diagnosis of NS or LS from clinical geneticists or paediatric cardiologists. A positive test result will provide a definite diagnosis of Noonan or LEOPARD syndrome as the mutation spectrum has been well defined and no cases of non-penetrance have been identified. A positive result will also allow differentiation from other phenotypically overlapping disorders which may require alternative interventions. Recurrence risks can also be provided to families as most cases are de novo in origin. A positive result will enable the appropriate assessment of growth, associated clotting factors and development. This will assist in decision-making regarding growth hormone treatment, provision of special education for delayed development and treatment using fresh frozen plasma to avoid life threatening haemorrhage. Assessment for coagulation defects will be important prior to corrective surgery for cardiac or other defects. Is there an alternative means of diagnosis or prediction that does not involve molecular diagnosis? If so (and in particular if there is a biochemical test) please state the added advantage of the molecular test There is no alternative laboratory test. Are there specific ethical, legal or social issues with this test? No. Please complete the referral pathway diagram on the following page and the testing criteria form. 7
8 Referral Pathway Template NOTE: Please use this page as a template. Please expand the test boxes manually as needed. TARGET POPULATION (Description) 1) Individuals with a possible diagnosis of Noonan or LEOPARD syndrome 2) Individuals with a familial mutation in the PTPN11, SOS1, RAF1 or KRAS genes 3) Prenatal cases in families with a known PTPN11, SOS1, RAF1 or KRAS mutation WHAT TYPE AND LEVEL OF PROFESSIONAL OR REFERRER DO YOU ACCEPT SAMPLES FROM? Clinical geneticists and paediatric cardiologists. PLEASE PROVIDE DETAILS OF HOW REFERRALS WILL BE ASSESSED FOR APPROPRIATENESS? Samples received from individuals with characteristic features of Noonan or LEOPARD syndrome will be appropriate for analysis. In practice, due to the high degree of heterogeneity in Noonan and LEOPARD syndrome, it is difficult to restrict analysis by phenotype alone. Samples will be analysed for stage 1 initially. Stages 2 and then stage 3 will be analysed upon request by the referring professional. Stage 1 dhplc of exons 2,3,4,7,8,12 and 13 of PTPN11 Stage 2 dhplc of exons 6,13 and 16 of RAF1 and exons 3, 6 and 10 of SOS1 Stage 3 dhplc of exons 7,8,11,13,14 and 16 of SOS1 and exons 1,2,3,4, and 4 isoform b KRAS HOW MANY TESTS DO YOU EXPECT TO PERFORM ANNUALLY?
9 UKGTN Testing criteria: Name of Disease(s): NOONAN SYNDROME 1; NS1 (163950) NOONAN SYNDROME 3 (609942) NOONAN SYNDROME 4; NS4 (610733) NOONAN SYNDROME 5; NS5 (611553) LEOPARD SYNDROME 1 (151100) LEOPARD SYNDROME 2 (611554) Name of gene(s): protein tyrosine phosphatase, non-receptor type 11 (Noonan syndrome 1) - PTPN11 (176876) son of sevenless homolog 1 (Drosophila) - SOS1 (182530) v-ki-ras2 Kirsten rat sarcoma viral oncogene homolog - KRAS (190070) v-raf-1 murine leukemia viral oncogene homolog 1 - RAF1 (164760) Patient name: Patient postcode: Date of birth: NHS number: Name of referrer: Title/Position: Lab ID: Referrals will only be accepted from one of the following: Referrer Clinical Geneticists Paediatric cardiologists Tick if this refers to you. Minimum criteria required for testing to be appropriate as stated in the Gene Dossier: Criteria Suspected diagnosis of Noonan/LEOPARD syndrome made by clinical geneticist or paediatric cardiologist Tick if this patient meets criteria If the sample does not fulfil the clinical criteria or you are not one of the specified types of referrer and you still feel that testing should be performed please contact the laboratory to discuss testing of the sample. 9
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) (A)-Testing
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names Osteogenesis Imperfecta
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Epileptic encephalopathy, early infantile 4. OMIM number for disease 612164 Disease
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) Glucocorticoid-remediable
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) (A)-Testing
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name HEMOCHROMATOSIS, TYPE 4; HFE4 OMIM number for disease #606069 Disease alternative
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Leber congenital amaurosis OMIM number for disease 204000 Disease alternative
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) (A)-Testing
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Amyotrophic Lateral Sclerosis 10 (ALS10) and Amyotrophic Lateral Sclerosis 6 (ALS6)
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Choroideremia OMIM number for disease 303100 Disease alternative names please
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Loeys-Dietz Syndrome OMIM number for disease 609192; 608967; 610380; 610168 Disease
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Genetic Causes of Hypothyroidism 1. Loss of function mutations in TSHR cause thyroid
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name OMIM number for disease 231300 Disease alternative names Please provide any alternative
More informationApplication to be an additional provider for existing test on the NHS Directory of Molecular Genetic Testing Additional Provider form
Application to be an additional provider for existing test on the NHS Directory of Molecular Genetic Testing Additional Provider form Disease: Gene: Cystic Fibrosis (CF) (carrier testing in reproductive
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name OMIM number for disease 147920 Disease alternative names Please provide any alternative
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Parkinson disease 8, automsomal dominant OMIM number for disease 607060 Disease
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISORDER/CONDITION POPULATION TRIAD Submitting laboratory: Exeter RGC Approved: Sept 2013 1. Disorder/condition
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name and description (please provide any alternative names you wish listed) (A)-Testing
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name OMIM number for disease Disease alternative names please provide any alternative
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISEASE/CONDITION POPULATION TRIAD Submitting laboratory: Cambridge RGC Approved: September 2012
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISEASE/CONDITION POPULATION TRIAD Submitting laboratory: Birmingham RGC Approved: September 2012
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name OMIM number for disease 312060 Disease alternative names please provide any alternative
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISEASE/CONDITION POPULATION TRIAD Submitting laboratory: Manchester RGC Approved: September 2013
More informationSubmitting Laboratory: London NE RGC GOSH
Submitting laboratory: London NE RGC GOSH 1. Disorder/condition approved name (please provide UK spelling if different from US) and symbol as published on the OMIM database (alternative names will be listed
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Polycystic Kidney Disease, Autosomal Dominant OMIM number for disease 173900 Disease
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISEASE/CONDITION POPULATION TRIAD Submitting laboratory: London North East RGC GOSH Approved: September
More informationMEDICAL GENOMICS LABORATORY. Non-NF1 RASopathy panel by Next-Gen Sequencing and Deletion/Duplication Analysis of SPRED1 (NNP-NG)
Non-NF1 RASopathy panel by Next-Gen Sequencing and Deletion/Duplication Analysis of SPRED1 (NNP-NG) Ordering Information Acceptable specimen types: Blood (3-6ml EDTA; no time limitations associated with
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISEASE/CONDITION POPULATION TRIAD Submitting laboratory: London North East RGC GOSH Approved: September
More informationIndication criteria for disease: Noonan syndrome [PTPN11, SOS1, RAF1, KRAS]
deutsche gesellschaft für humangenetik e.v. Indication Criteria for Genetic Testing Evaluation of validity and clinical utility german society of human genetics www.gfhev.de Indication criteria for disease:
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISORDER/CONDITION POPULATION TRIAD Submitting laboratory: Cardiff SAS Porphyria Approved: Sept
More informationTest Information Sheet
Noonan Spectrum and RASopathies Panel (19 genes) Disorder also known as: Noonan Spectrum disorders; Ras/MAPK pathway related disorders Panel Gene List: PTPN11; SOS1; RAF1; KRAS; HRAS; BRAF; MAP2K1 (MEK1);
More informationR.C.P.U. NEWSLETTER. E Mail: Website:
R.C.P.U. NEWSLETTER Editor: Heather J. Stalker, M.Sc. Director: Roberto T. Zori, M.D. R.C. Philips Research and Education Unit Vol. XX No. 2 A statewide commitment to the problems of mental retardation
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Submitting laboratory: Bristol RGC 1. Disorder/condition approved name and symbol as published on the OMIM database (alternative
More informationNeurofibromatosis type 1 and RASopathies
Neurofibromatosis type 1 and RASopathies Dawn Siegel, MD Medical College of Wisconsin American Academy of Dermatology San Diego, CA February 19 th, 2018 Neurofibromatosis Type 1 NF1- diagnostic criteria
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider TEST DISORDER/CONDITION POPULATION TRIAD Submitting laboratory: Bristol RGC Approved: Sept 2013 1. Disorder/condition
More informationGet a more complete picture into your patient's pregnancy with PreSeek
PRENATAL Expecting a baby is an exciting and mysterious time. And it s natural for your patient to wonder if they have a healthy pregnancy. Introducing PreSeek, the most comprehensive, single gene, cell-free
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider Submitting laboratory: Leeds RGC 1. Disorder/condition approved name (please provide UK spelling if different
More informationUKGTN Testing Criteria
UKGTN Testing Criteria Test name: Inherited Bone Marrow Failure Syndromes 44 Gene Panel Approved name disorder/(s): See Appendix 1 Approved name (s): See Appendix 1 (s): (s): Patient name: Patient postcode:
More informationCURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE. Dr. Bahar Naghavi
2 CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE Dr. Bahar Naghavi Assistant professor of Basic Science Department, Shahid Beheshti University of Medical Sciences, Tehran,Iran 3 Introduction Over 4000
More informationNoonan Syndrome: A Case Report
Annals of Health Research Volume 4, Issue No 1: 82-87 January-June 2018 DOI: 10.30442/ahr.0401-1-11 ORIGINAL RESEARCH Noonan Syndrome: A Case Report Khan F, Waqar S*, Jamal NU, Saleem A Cardiology Ward,
More information22q11.2 DELETION SYNDROME. Anna Mª Cueto González Clinical Geneticist Programa de Medicina Molecular y Genética Hospital Vall d Hebrón (Barcelona)
22q11.2 DELETION SYNDROME Anna Mª Cueto González Clinical Geneticist Programa de Medicina Molecular y Genética Hospital Vall d Hebrón (Barcelona) Genomic disorders GENOMICS DISORDERS refers to those diseases
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Submitting laboratory: Bristol RGC 1. Disorder/condition approved name and symbol as published on the OMIM database (alternative
More informationWhat s New in Newborn Screening?
What s New in Newborn Screening? Funded by: Illinois Department of Public Health Information on Newborn Screening Newborn screening in Illinois is administered by the Illinois Department of Public Health.
More informationMEDICAL GENOMICS LABORATORY. Peripheral Nerve Sheath Tumor Panel by Next-Gen Sequencing (PNT-NG)
Peripheral Nerve Sheath Tumor Panel by Next-Gen Sequencing (PNT-NG) Ordering Information Acceptable specimen types: Blood (3-6ml EDTA; no time limitations associated with receipt) Saliva (OGR-575 DNA Genotek;
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider Submitting laboratory: Sheffield RGC 1. Disorder/condition approved name (please provide UK spelling
More informationCongenital Heart Disease How much of it is genetic?
Congenital Heart Disease How much of it is genetic? Stephen Robertson Curekids Professor of Paediatric Genetics Dunedin School of Medicine University of Otago Congenital Heart Disease The most common survivable
More informationAn Introduction to mitochondrial disease.
9 th September 2017 An Introduction to mitochondrial disease. Dr Andy Schaefer Consultant Neurologist and Clinical Lead NHS Highly Specialised Rare Mitochondrial Disease Service and Wellcome Trust Centre
More informationPractical challenges that copy number variation and whole genome sequencing create for genetic diagnostic labs
Practical challenges that copy number variation and whole genome sequencing create for genetic diagnostic labs Joris Vermeesch, Center for Human Genetics K.U.Leuven, Belgium ESHG June 11, 2010 When and
More informationThe first non-invasive prenatal test that screens for single-gene disorders
The first non-invasive prenatal test that screens for single-gene disorders the evolution of NIPT A non-invasive prenatal test that screens multiple genes for mutations causing severe genetic disorders
More informationPrices listed correspond to institutional rates only; please contact the lab for insurance rates.
Prices listed correspond to institutional rates only; please contact the lab for insurance rates. Genetic Test Neurofibromatosis Type 1 - NF1 and Legius syndrome SPRED1 $1400 (NF1/SPRED1 negative) 81408,
More informationPrices listed correspond to institutional rates only; please contact the lab for insurance rates.
Prices listed correspond to institutional rates only; please contact the lab for insurance rates. Genetic Test Neurofibromatosis Type 1 - NF1 and Legius syndrome SPRED1 $1400 (NF1/SPRED1 negative) 81408,
More informationNGS Types of gene dossier applications UKGTN can evaluate
NGS Types of gene dossier applications UKGTN can evaluate Jo Whittaker on behalf of the Genetic Test Evaluation Working Group & UKGTN Project team NGS used in a number of ways Replacement technology for
More informationNoonan syndrome and related disorders: Alterations in growth and puberty
Rev Endocr Metab Disord (2006) 7:251 255 DOI 10.1007/s11154-006-9021-1 Noonan syndrome and related disorders: Alterations in growth and puberty Jacqueline A. Noonan Published online: 20 December 2006 #
More informationUKGTN Testing Criteria
Test name: Neonatal Diabetes 22 Gene Panel UKGTN Testing Criteria Approved name and symbol of disorder/condition(s): See Appendix 1 Approved name and symbol of gene(s): See Appendix 1 number(s): number(s):
More informationRecognizing Genetic Red Flags in Clinical Evaluations
Recognizing Genetic Red Flags in Clinical Evaluations ACGME Sub-competencies / Developmental Milestones Addressed Patient Care: Gather essential and accurate information about the patient; Make informed
More informationPrices listed correspond to institutional rates only; please contact the lab for insurance rates.
Prices listed correspond to institutional rates only; please contact the lab for insurance rates. Genetic Test TAT ** Neurofibromatosis Type 1 - NF1 and Legius syndrome SPRED1 $1400 (NF1/SPRED1 negative)
More informationTHE ROLE OF MOLECULAR AUTOPSY IN 2014: FROM THE ANATOMICAL THEATRE TO THE DOUBLE HELIX. Gaetano Thiene, MD
THE ROLE OF MOLECULAR AUTOPSY IN 2014: FROM THE ANATOMICAL THEATRE TO THE DOUBLE HELIX Gaetano Thiene, MD Torino, October 23, 2014 The Role of the Autopsy in SD To establish or consider: whether the death
More informationTalking Genomes with Your Patients. Meagan Cochran, MS, CGC Certified Genetic Counselor HudsonAlpha Institute for Biotechnology
Talking Genomes with Your Patients Meagan Cochran, MS, CGC Certified Genetic Counselor HudsonAlpha Institute for Biotechnology Objectives Review the importance of physician familiarity with genomic testing
More information2011 HCM Guideline Data Supplements
Data Supplement 1. Genetics Table Study Name/Author (Citation) Aim of Study Quality of life and psychological distress quality of life and in mutation psychological carriers: a crosssectional distress
More informationADULT CONGENITAL HEART DISEASES NURSING CARE: PRESENT AND FUTURE CHALLENGES. Haitham Kanan, Clinical Instructor King Faisal specialist Hospital
ADULT CONGENITAL HEART DISEASES NURSING CARE: PRESENT AND FUTURE CHALLENGES Haitham Kanan, Clinical Instructor King Faisal specialist Hospital Nursing Development and Saudization Objectives es At the
More informationSupporting Online Material for
www.sciencemag.org/cgi/content/full/1124642/dc1 Supporting Online Material for Germline Mutations in Genes within the MAPK Pathway Cause Cardio-facio-cutaneous Syndrome Pablo Rodriguez-Viciana, Osamu Tetsu,
More informationThe Fetal Cardiology Program
The Fetal Cardiology Program at Texas Children s Fetal Center About the program Since the 1980s, Texas Children s Fetal Cardiology Program has provided comprehensive fetal cardiac care to expecting families
More informationUKGTN Testing Criteria
UKGTN Testing Criteria Approved name and symbol of disease/condition(s): Retinal Degeneration panel test Approved name and symbol of gene(s): a panel of 105 genes, variants of which have been shown to
More informationPrecision Medicine and Genetic Counseling : Is Yes always the correct answer?
Precision Medicine and Genetic Counseling : Is Yes always the correct answer? Beverly M. Yashar, MS, PhD, CGC Director, Graduate Program in Genetic Counseling Professor, Department of Human Genetics. (yashar@umich.edu)
More informationMEDICAL GENOMICS LABORATORY. Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG)
Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG) Ordering Information Acceptable specimen types: Fresh blood sample (3-6 ml EDTA; no time limitations associated with receipt)
More informationMOLECULAR DIAGNOSIS for X-LINKED INTELLECTUAL DISABILITY
MOLECULAR DIAGNOSIS for X-LINKED INTELLECTUAL DISABILITY Intellectual disability (ID) or mental retardation is characterized by significant limitations in cognitive abilities and social/behavioral adaptive
More informationThe Clinical Spectrum of RASopathies
The Clinical Spectrum of RASopathies Divya Agarwal, Ratna D Puri, Achint Kaur, Sunita Bijarnia-Mahay and IC Verma Center of Medical Genetics, Sir Ganga Ram Hospital, New Delhi Email: dr.divya2512@gmail.com
More informationInterpretation can t happen in isolation. Jonathan S. Berg, MD/PhD Assistant Professor Department of Genetics UNC Chapel Hill
Interpretation can t happen in isolation Jonathan S. Berg, MD/PhD Assistant Professor Department of Genetics UNC Chapel Hill With the advent of genome-scale sequencing, variant interpretation is increasingly
More informationsyndromes associated with brain malformation - dysmorphology Renske Oegema, MD, PhD clinical geneticist UMC Utrecht, NL Milano, 2018
syndromes associated with brain malformation - dysmorphology Renske Oegema, MD, PhD clinical geneticist UMC Utrecht, NL Milano, 2018 Miller Dieker syndrome, del 17p13.3 incl LIS1 en YWHAE Postnatal mild
More informationCardiology Competency Based Goals and Objectives
Cardiology Competency Based Goals and Objectives COMPETENCY 1. Patient Care. Provide family centered patient care that is developmentally and age appropriate, compassionate, and effective for the treatment
More informationCorporate Medical Policy
Corporate Medical Policy Genetic Testing for Marfan Syndrome, Thoracic Aortic Aneurysms and File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_marfan_syndrome_thoracic_aortic_aneurysms_and_dissections_and_relat
More informationA guide to understanding variant classification
White paper A guide to understanding variant classification In a diagnostic setting, variant classification forms the basis for clinical judgment, making proper classification of variants critical to your
More informationAgro/Ansc/Bio/Gene/Hort 305 Fall, 2017 MEDICAL GENETICS AND CANCER Chpt 24, Genetics by Brooker (lecture outline) #17
Agro/Ansc/Bio/Gene/Hort 305 Fall, 2017 MEDICAL GENETICS AND CANCER Chpt 24, Genetics by Brooker (lecture outline) #17 INTRODUCTION - Our genes underlie every aspect of human health, both in function and
More informationTHE SPECTRUM OF PAEDIATRIC CARDIAC DISEASE IN VANUATU. Dr Annette Garae (PGDCH)
THE SPECTRUM OF PAEDIATRIC CARDIAC DISEASE IN VANUATU Dr Annette Garae (PGDCH) Introduction Heart disease in children can be either congenital or acquired. Congenital heart disease (CHD) accounts for nearly
More informationDR. SHAHJADA SELIM. Growth Hormone Deficiency. Subdivisions of Growth Hormone Deficiency. General Discussion. Signs & Symptoms
Growth Hormone Deficiency NORD gratefully acknowledges Joe Head, NORD Intern and Richard A. Levy, MD, Director of Pediatric Endocrinology Section, Rush University, for their assistance in the preparation
More informationISPUB.COM. Cardiofaciocutaneous Syndrome With Occipital Encephalocele. S Shahid INTRODUCTION CASE REPORT
ISPUB.COM The Internet Journal of Pediatrics and Neonatology Volume 6 Number 2 Cardiofaciocutaneous Syndrome With Occipital Encephalocele S Shahid Citation S Shahid. Cardiofaciocutaneous Syndrome With
More information: Provide cardiovascular preventive counseling to parents and patients with specific cardiac diseases about:
Children s Hospital & Research Center Oakland Cardiology Primary Goals for this Rotation 5.13 GOAL: Prevention, Counseling and Screening (Cardiovascular). Understand the role of the pediatrician in preventing
More informationGenetics/Genomics: role of genes in diagnosis and/risk and in personalised medicine
Genetics/Genomics: role of genes in diagnosis and/risk and in personalised medicine Lynn Greenhalgh, Macmillan Cancer and General Clinical Geneticist Cancer Genetics Service Cancer is common 1 in
More informationArchives of Dermatological Research
Archives of Dermatological Research Phenotypic diversity of patients with LEOPARD syndrome carrying the worldwide recurrent p.tyr9cys PTPN mutation --Manuscript Draft-- Manuscript Number: Full Title: Article
More informationIndication criteria for disease: Mucopolysaccharidosis type II
deutsche gesellschaft für humangenetik e.v. Indication Criteria for Genetic Testing Evaluation of validity and clinical utility german society of human genetics www.gfhev.de Indication criteria for disease:
More information2013/14 NHS STANDARD CONTRACT FOR STICKLER SYNDROME DIAGNOSTIC SERVICE (CHILDREN) D12/S(HSS)/d. Stickler syndrome diagnostic service(children)
D12/S(HSS)/d 2013/14 NHS STANDARD CONTRACT FOR STICKLER SYNDROME DIAGNOSTIC SERVICE (CHILDREN) SECTION B PART 1 - SERVICE SPECIFICATIONS Service Specification No. Service Commissioner Lead Provider Lead
More informationCanadian College of Medical Geneticists (CCMG) Cytogenetics Examination. May 4, 2010
Canadian College of Medical Geneticists (CCMG) Cytogenetics Examination May 4, 2010 Examination Length = 3 hours Total Marks = 100 (7 questions) Total Pages = 8 (including cover sheet and 2 pages of prints)
More informationProblem set questions from Final Exam Human Genetics, Nondisjunction, and Cancer
Problem set questions from Final Exam Human Genetics, Nondisjunction, and ancer Mapping in humans using SSRs and LOD scores 1. You set out to genetically map the locus for color blindness with respect
More informationGenetics update and implications for (General) Practice
Genetics update and implications for (General) Practice May 12 th 2018 Women s Health Symposium Clearwater Estate Dr Kate Gibson MB BCh, MRCP, FRACP Topics NZ Clinical Genetics delivery New Technologies
More informationUK Genetic Testing Network Marfan syndrome testing guideline workshop
UK Genetic Testing Network Marfan syndrome testing guideline workshop Executive summary 5 th September 2012, 10.30-3.15pm Royal College of Physicians, London Meeting report The UK Genetic Testing Network
More informationA rare variant in MYH6 confers high risk of sick sinus syndrome. Hilma Hólm ESC Congress 2011 Paris, France
A rare variant in MYH6 confers high risk of sick sinus syndrome Hilma Hólm ESC Congress 2011 Paris, France Disclosures I am an employee of decode genetics, Reykjavik, Iceland. Sick sinus syndrome SSS is
More informationM ultiple lentigines LEOPARD syndrome (MIM )
1of6 ONLINE MUTATION REPORT Clinical and molecular analysis of 30 patients with multiple lentigines LEOPARD syndrome A Sarkozy, E Conti, M Cristina Digilio, B Marino, E Morini, G Pacileo, M Wilson, R Calabrò,
More informationSpecialised Services Commissioning Policy: CP34 Circumcision for children
Specialised Services Commissioning Policy: CP34 Circumcision for children March 2019 Version 3.0 Document information Document purpose Document name Author Policy Circumcision for Children Welsh Health
More informationCardio-Facio-Cutaneous Syndrome
Cardio-Facio-Cutaneous Syndrome - A Case Report - Feng-Jie Lai Hamm-Ming Sheu We report on a 9-year-old boy with typical manifestations of cardio-facio-cutaneous (CFC) syndrome. The patient was affected
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider Submitting laboratory: Birmingham RGC 1. Disorder/condition approved name (please provide UK spelling
More informationCardiac Considerations and Care in Children with Neuromuscular Disorders
Cardiac Considerations and Care in Children with Neuromuscular Disorders - importance of early and ongoing treatment, management and available able medications. Dr Bo Remenyi Department of Cardiology The
More informationN oonan syndrome (MIM ), an autosomal dominant
704 LETTER TO JMG Correlation between gene and congenital heart defects in and LEOPARD s A Sarkozy, E Conti, D Seripa, M C Digilio, N Grifone, C Tandoi, V M Fazio, V Di Ciommo, B Marino, A Pizzuti, B Dallapiccola...
More informationSNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY.
SAMPLE REPORT SNP Array NOTE: THIS IS A SAMPLE REPORT AND MAY NOT REFLECT ACTUAL PATIENT DATA. FORMAT AND/OR CONTENT MAY BE UPDATED PERIODICALLY. RESULTS SNP Array Copy Number Variations Result: LOSS,
More informationHeterotaxie PCD (Primaire ciliaire dyskinesie) panel
Heterotaxie PCD (Primaire ciliaire dyskinesie) panel versie V1 (92 genen) Centrum voor Medische Genetica Gent Gene OMIM gene ID Associated phenotype, OMIM phenotype ID, phenotype mapping key and inheritance
More informationIntroduction to Genetics
Introduction to Genetics Table of contents Chromosome DNA Protein synthesis Mutation Genetic disorder Relationship between genes and cancer Genetic testing Technical concern 2 All living organisms consist
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) Sept 2015 Review: Sept 2018 Bulletin 227: EXOGEN ultrasound bone healing system used for the management of long bone fractures JPC Recommendations:
More informationLENTIGO SIMPLEX. Epidemiology
LENTIGO SIMPLEX Epidemiology The frequency of lentigo simplex in children and adults has not been determined. There does not appear to be a racial or gender predilection. Lentigo simplex is the most common
More informationSotos syndrome. Nazneen Rahman Institute of Cancer Research
Sotos syndrome Nazneen Rahman Institute of Cancer Research Sotos syndrome- background Sporadic condition Distinctive facial appearance Overgrowth (tall with big heads) Learning difficulties Other variably
More informationGaucher disease 3/22/2009. Mendelian pedigree patterns. Autosomal-dominant inheritance
Mendelian pedigree patterns Autosomal-dominant inheritance Autosomal dominant Autosomal recessive X-linked dominant X-linked recessive Y-linked Examples of AD inheritance Autosomal-recessive inheritance
More informationPolicy Specific Section: Medical Necessity and Investigational / Experimental. October 14, 1998 March 28, 2014
Medical Policy Genetic Testing for Colorectal Cancer Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date: Effective Date: October
More information